Debiopharm Deploys Genialis Expressions Platform to Enhance Biomarker Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3h ago
0mins
Source: Businesswire
- Platform Deployment: Debiopharm has deployed the Genialis Expressions software platform within its cloud infrastructure to support biomarker discovery and multiomics data analytics, thereby enhancing data processing efficiency and streamlining workflows.
- Collaboration Extension: This agreement extends the multi-year collaboration between the companies, granting Debiopharm access to Genialis' integrated technology stack, which ensures greater consistency in dataset comparisons across different studies, thereby improving research reliability.
- Data Standardization: Genialis Expressions addresses the challenge of relying on various vendors and workflows for omics data processing by establishing a centralized platform, ensuring consistency across all omics datasets and providing clearer success predictions for drug development.
- AI-Driven Modeling: The platform not only delivers standardized molecular outputs but also serves as the entry point to the broader Genialis software ecosystem, supporting comprehensive AI-based modeling and the development of biology-driven biomarker algorithms, thus driving innovation and efficiency throughout the drug development lifecycle.
Analyst Views on GENI
Wall Street analysts forecast GENI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GENI is 14.50 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 10.540
Low
10.00
Averages
14.50
High
16.00
Current: 10.540
Low
10.00
Averages
14.50
High
16.00
About GENI
Genius Sports Limited is the official data, technology and broadcast partner that powers the ecosystem connecting sports, betting and media. It operates through one segment, which consists of providing access to Betting Content Technology, Content and Services; Media Technology Content and Services; and Sports Technology and Services. It builds and supplies technology and services that allow sports leagues to collect, analyze and monetize their data with added tools to deepen fan engagement. It provides sports leagues with bespoke monitoring technology and education services to help protect their competitions and athletes from the threats of match fixing and betting-related corruption. It offers official data, outsourced bookmaking, trading/risk management services and live audio-visual game content that is derived from its streaming partnerships with sports leagues. Its offerings include Live sports data, Pre-game and in-game odds feeds, and BetVision, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
